drugset / Trial / NCT07545681
A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria
NaSequentialOpen-labelTreatment
Summary
The study will evaluate the safety and efficacy of a new antimalarial drug GSK3772701 (a pyrrolidinamide), using different doses and treatment durations, in adult participants with uncomplicated Plasmodium (P.) falciparum malaria.
Timeline
- Start
- 2026-07-28
- Primary completion
- 2027-07-29
- Completion
- 2027-07-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GSK3772701 | Unknown | 50 mg | Oral |
| Subject | GSK3772701 | Unknown | 150 mg | Oral |
| Subject | GSK3772701 | Unknown | 400 mg | Oral |
| Subject | GSK3772701 | Unknown | 600 mg | Oral |
| Subject | GSK3772701 | Unknown | 900 mg | Oral |